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Ras mutations are present in 40–50% of colorectal cancers. Inactivating this oncogene may therefore reduce proliferation
capacity. In order to target ras we studied the transduction efﬁcacy and anti tumour activity of an adenoviral vector expressing
an intracellular, neutralizing single chain antibody to p21-ras (Y28). In in vitro studies transfection levels of the K-ras mutated rat
colon carcinoma cell line CC531 were studied using the LacZ marker gene. In our in vivo liver metastases model different
routes of administration were evaluated to determine which regimen resulted in the best transfection levels and tumour
responses: intravenous injection, intratumoural injection, isolated liver perfusion, or hepatic artery infusion. CC531 cells are
readily transfected in vitro, resulting in signiﬁcant inhibition of tumour cell proliferation by the Y28 construct. Intravenous
injection did not result in any measurable transfection. Intratumoural injection resulted only in the transfection of tumour cells
along the needle track. IHP as well as single HAI achieved low transfection levels of tumour tissue. Expression of Y28 was
demonstrated in tumours after IT injection, HAI and IHP. Whereas, repeated HAI’s clearly achieved expression in and around
tumour associated vessels. Only ﬁve times repeated HAI’s with Y28 resulted in a tumour response: in all animals tumour
growth was inhibited, and in three rats out of eight a complete regression of the liver tumours was observed.
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After resection of the primary tumour recurrent colorectal carcino-
ma occurs in about 50% of patients. In these patients the liver is
the major site of metastatic disease (Sugarbaker, 1994). Patients
with resectable liver metastases may have a partial hepatectomy
with a 5 year survival rate of 25–30% (Hughes, 1988; Steele and
Ravikumar, 1989; Scheele et al, 1995). On the other hand the
natural history of patients with untreated liver metastases shows
a 5-year survival rate of 0–3% (Wood et al, 1976).
Colorectal carcinogenesis is associated with multiple genetic
alterations. Ras mutations occur in an early stage of progression
from adenoma to carcinoma. Ras mutations are present in 40–
50% of human colorectal tumours (Spandidos et al, 1995). Physio-
logically, the ras gene leads to the production of p21-ras, a protein
that catalyses the hydrolysis of guanosine triphosphate to guano-
sine diphosphate, and in this way controls cell proliferation by
regulating signal transduction pathways (Bos, 1989). Inhibition of
expression of mutated ras has been shown to cause tumour growth
inhibition and apoptosis in human and murine tumour cell lines
(Mukhopadhyay et al, 1991; Georges et al, 1993; Shirasawa et al,
1993; Cochet et al, 1998, 1999).
In the development of gene therapy protocols it has been often
shown that data from in vitro experiments do not always predict
anti-tumour effects in vivo. The main reason for this may be insuf-
ﬁcient tumour targeting. By locoregional administration of the
genetic construct, tumour targeting may be improved and conse-
quently result in more favourable responses. Previously, we have
demonstrated successful transfection and anti-tumour activity in
a rat sarcoma model with isolated limb perfusion (de Roos et al,
2000; de Wilt et al, 2001).
Isolated liver perfusion and hepatic artery infusion are used in
surgical oncology trials for the administration of chemotherapeu-
tics and cytokines in patients with liver tumours (Marinelli et al,
1990; Marinelli et al, 1991; Kemeny et al, 1994; Kuppen et al,
1997; Alexander et al, 1998; de Vries et al, 1998). High local drug
concentrations can be achieved at the tumour site by means of
isolated hepatic perfusion (IHP), a technique with minimal
systemic exposure. de Roos et al (1997) and others have already
demonstrated effective administration of adenoviral vectors via
IHP (van der Eb et al, 1998a,b).
Repetitive locoregional administration of drugs can be achieved
by regional infusions via the hepatic artery (Riemenschneider et al,
1988; Miyazaki et al, 1993; Kemeny et al, 1994). Thus repeated
delivery of adenoviral vectors via the hepatic artery may further
increase the efﬁcacy of transfection.
We anticipated that the route of delivery plays a crucial role in
optimizing transduction efﬁcacy and more importantly in anti-
tumour activity. We report here on a transduction efﬁcacy study
of an adenoviral vector encoding the LacZ marker gene, admini-
strated to the liver via systemic and different locoregional routes
of administration, and subsequently on the antitumour activity
of an adenoviral vector expressing a single chain antibody to
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MATERIALS AND METHODS
Recombinant adenovirus constructs
AV1.0CMV.Y28 is a recombinant replication-deﬁcient adenovirus
vector expressing the Y28 gene. It encodes the hypervariable
regions of an anti-p21-ras single chain antibody driven by the
human cytomegalovirus (CMV) promoter. It is derived from the
rat Y13-259 monoclonal antibody to p21-ras (Furth et al, 1982;
Werge et al, 1990; Cochet et al, 1998). The Y28 expression unit,
which also contains the bovine Growth Hormone polyadenylation
signal (bGH polyA), replaces the E1 adenovirus region. The
AV1.0CMV.Y28 backbone is an E1/E3 deleted human adenovirus
serotype 5. This construct was subjected to multiple plaque puriﬁ-
cation and produced in the 293 cell line (human transformed
primary embryonal kidney cell line) trans-complementing for E1
gene products. Adenovirus was recovered from cell culture super-
natant and puriﬁed by two rounds of cesium chloride
ultracentrifugation. Puriﬁed virus was then gel-ﬁltered on a PD10
column with a PBS buffer containing 0.5 mM MgCl2, 0.5 mM
CaCl2 and 10% glycerol. Virus stock was aliquoted and stored at
7808C until used. The batch used, met the preclinical grade speci-
ﬁcations (Quality Control analyses), in regard to sterility,
endotoxins, mycoplasma, viral particles and plaque forming unit
titers. AV1.0CMV.LacZ and AV1.0CMV are also recombinant
replication-deﬁcient adenovirus vectors constructed on the same
basis of an E1 and E3 deleted human adenovirus type 5 backbone
and produced in 293 packaging cell line. The former expresses the
E. coli derived ß-galactosidase protein that can be detected by
histochemistry in order to access the transduction efﬁcacy of the
vector. The latter contains only the CMV promoter and SV40
signal without any transgene inserted. This ‘empty’ construct has
been used as the control vector in all experiments.
Tumour
The colon carcinoma cell line CC531, a 1,2-dimethylhydrazine-
induced, moderately differentiated adenocarcinoma was used
(Marquet et al, 1984). The cell line is transplantable in syngeneic
WAG/RIJ rats. It exhibits a mutated K-ras gene in codon 12
(GGT to GAT), changing glycine to aspartic acid (unpublished
data, laboratory of Dr R Koesters, DKFZ-Heidelberg, Germany).
The tumour is weakly immunogenic, as determined by the immu-
nization method of Prehn and Main (1957). The tumour can also
be maintained in tissue culture. New tumour was produced from
this culture by subcapsularly implantation in the liver. It is a rela-
tively slowly progressing and poorly vascularized tumour. In vivo
tumours were subsequently passaged serially.
In vitro bioassay
CC531 cells were grown in RPMI 1640 (Gibco BRL, Paisley, UK)
supplemented with 10% foetal calf serum (Harlan/Sera-Lab, UK),
1% penicillin (5000 IU ml
71), 1% streptomycin (5000 IU ml
71)
and 1% L-glutamine (200 mM) (all Gibco BRL) in a humidiﬁed
incubator at 378C and 5% CO2. Before usage, the cells were trypsi-
nized (1 min, 378C), centrifuged (5 min, 700 g), resuspended and
the viability measured by Trypan blue exclusion. Viability always
exceeded 85%. For in vitro testing of proliferation inhibition,
1.0610
4 cells were seeded in ﬂat-bottomed 96-well microtiter plates
(Costar, USA). After 24 h the cells were incubated with different
concentrations of the Y28 or empty construct for 48 h ranging from
a multiplicity of infection (MOI) of 1–2.0610
5. Afterwards, cells
were washed with PBS and ﬁxed for 30 min with 10% trichloro-
acetic acid at 48C. Growth of tumour cells was measured using
the sulpharhodamine-B assay according to the method of Skehan
et al (1990). Tumour cell proliferation was measured using the
formula: tumour growth=(test well/control)6100%. Five indepen-
dent tests were performed for each point on the line.
Animals
We used male inbred WAG/RIJ rats, weighing 250–300 g, obtained
from Harlan-CPB (Austerlitz, The Netherlands). The rats were fed
a standard laboratory diet. All animals were housed under standard
conditions of light and accommodation. The protocol was
approved by the committee for animal research of the Erasmus
University, Rotterdam, The Netherlands. The experimental proto-
cols adhered to the rules outlined in the Dutch Animal
Experimentation Act of 1977 and the published Guidelines of the
UKCCCR for the Welfare of Animals in Experimental Neoplasia
(UKCCCR, 1998).
In vivo colorectal liver metastases model
Following a standardized protocol, small viable CC531 tumour
fragments of 162 mm were implanted under the liver capsule,
one in the left and one in the right side of the left liver lobe, using
a 19 G Luerlock needle. Experiments started at a tumour diameter
of 5–6 mm, which was reached about 14 days after implantation
of the tumour. When tumours reached a size of 25 mm in
diameter or animals showed obvious signs of discomfort the
animals were sacriﬁced.
Isolated hepatic perfusion
This rat isolated liver perfusion model has been described in detail
earlier by van IJken et al (2000). Brieﬂy, the perfusion circuit
consisted of an arterial inﬂow limb, a venous outﬂow limb and a
collection reservoir/oxygenator (Figure 1A). The circuit was primed
with 10 ml Haemaccel (Behring Pharma, Amsterdam, The Nether-
lands). Arterial ﬂow of 5 ml min
71 was maintained with a low-
ﬂow roller pump (Watson Marlow type 505 U, Falmouth, UK).
Rats were perfused for 10 min with oxygenated Haemaccel and
1.0610
11 virus particles (v.p.), which was determined as the maxi-
mum tolerated dose (MTD), in a pilot study performed previously.
Fifty IU of Heparin (Heparine Leo, The Netherlands) was added to
the perfusate. The perfusate was oxygenated in the reservoir with a
mixture of O2/CO2 (95%:5%) and was kept at 38–398C by means
of a heat exchanger and a warm water bath. A temperature probe
was positioned in the lumen of the arterial catheter, 5 cm away
from the catheter tip. Afterwards, a wash out to remove all left
viruses was performed by perfusing with 10 ml of oxygenated
Haemaccel.
Surgical procedure of the isolated hepatic perfusion Anaesthe-
sia was induced and maintained with ether (Merck, Darmstadt,
Germany). During the surgical procedure, with an average duration
of 60–75 min, rats were kept at a constant temperature using a
warmed mattress. A mid-line laparotomy was performed and the
hepatic ligament exposed. The gastroduodenal side branch of the
common hepatic artery was cannulated, positioning the tips of
the cannula (0.025 inch outer diameter (OD), 0.012 inner diameter
(ID), (Dow Corning, Michigan, USA)) in the proper hepatic artery.
Through a small inguinal incision the femoral vein was exposed.
To collect hepatic venous outﬂow a silicon cannula (0.047 inch
OD, 0.025 ID), (Dow Corning, Michigan, USA) was introduced
in the femoral vein and moved up into the caval vein positioning
the tip of the cannula at the level of the hepatic veins.
Isolation of the hepatic vascular bed was obtained by tempora-
rily ligating the common hepatic artery and the portal vein. The
venous outﬂow limb was isolated by temporarily clamping the
supra hepatic caval vein and by applying a temporary ligature
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 436–442around the infra-hepatic caval vein containing the cannula, cranial
to the right adrenal vein. The mesenteric artery was temporarily
clamped in order to reduce splanchnic blood pressure.
Following the procedure, the clamps on caval vein, portal vein,
hepatic artery and mesenteric artery were released. The gastroduo-
denal artery and femoral vein were ligated and the gastroduodenal
and femoral cannulas were removed.
Single time and repeated hepatic artery infusion
Single time hepatic artery infusion Anaesthesia was carried out
with Hypnorm (Janssen Animal Health, Beerse, Belgium) and
Ketamine (Apharmo B.V., Arnhem, The Netherlands). During the
total procedure, which took on average 2 h and 20 min, rats were
kept at a constant temperature with a warmed mattress and a heat
producing light bulb. A mid-line laparotomy was performed and
the hepatic ligament exposed. The gastroduodenal side branch of
the common hepatic artery was then cannulated, positioning the
tips of the cannula in the proper hepatic artery (Figure 1B). The
cannula was connected to the infusion pump (B. Braun, Melsungen
AG, Germany). 2.5610
11 v.p. (MTD) were dissolved in 1.5 ml of
0.9% NaCl/fractionated heparin solution (Fragmin, Pharmacia
and Upjohn, Woerden, The Netherlands) (2500 IU Fragmin per
100 ml 0.9% NaCl). The viruses were infused in 1 h. Afterwards
the cannula was ﬂushed with 0.9% NaCl in order to infuse the
remaining viruses in the cannula. During the infusion the arterial
hepatic blood supply was maintained. At the end of the procedure
the gastroduodenal artery was ligated and the cannula removed.
Repeated hepatic artery infusion After positioning of the
cannula in the gastroduodenal side branch of the hepatic artery
as described above, the cannula was led through a ﬂexible tube
and connected via a bubble trap to a continuous 0.9% NaCl/Frag-
min solution infusion pump which was set at a continuous
infusion rate of 0.5 ml h
71. Treatment with 2.5610
11 v.p.
(MTD) started at the day of operation and was repeated with
2.5610
11 v.p. every other day. The animals stayed in an adjusted
ﬁlter top cage during the treatment schedule.
Intravenous injection
Anaesthesia was induced and maintained with ether. A volume of
200 ml of PBS containing 2.5610
11 v.p. (MTD) was slowly injected
into the penile vein using a syringe with a 25 G needle.
Intratumoural injection
Anaesthesia was induced and maintained with ether. A mid-line
laparotomy was performed and the tumours were exposed. Using
a syringe with a 28 G needle, 5.0610
10 v.p. (MTD) in 50 ml sterile
PBS were injected centrally in each tumour.
In vivo transduction efﬁcacy study
Experiments started at a diameter between 5 and 6 mm. In order
to determine the transduction efﬁcacy, tumour-bearing rats were
treated with the AV1.0CMV.LacZ construct intravenously, by intra-
tumoural injection, via a single time hepatic artery infusion,
isolated hepatic perfusion and hepatic artery infusion repeated ﬁve
times. PBS solution was used as a control. Twenty-four hours after
treatment the animals were sacriﬁced. Tumours, liver and spleen
were taken out, snap frozen in liquid nitrogen and stored at
7808C until further usage.
X-Gal staining on cultured cells and cryosections
Staining of cultured cells 1.0610
4 CC531 cells were seeded in
ﬂat-bottomed 96-well microtiter plates. After 24 h the cells were
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Figure 1 Schematic representation of (A) an isolated hepatic perfusion (IHP) and (B) a hepatic artery infusion (HAI).
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construct ranging from a MOI of 1 up to 2.0610
5. Then, cells
were washed with PBS and ﬁxed for 30 min with 4% paraformal-
dehyde at 48C. The cells were washed three times with PBS and
stained with X-gal staining solution overnight at 378C. This solu-
tion is a mixture of solution A: K4Fe(CN)6.3H2O5 m M,
K3Fe(CN)6 5m M in wash buffer (MgCl2 2m M, deoxycholate
0.01%, NP-40 0.02% in 0.1 M sodium phosphate buffer pH 7.8)
and solution B: 5-bromo, 4-chloro, 3-indolyl b-d-galactopyrano-
side 50 mg ml
71 in dimethyl formamide) at ratio of 50:1. The
cells were then washed once with PBS and stored at 48C.
Staining of cryosections Cryosections of snap frozen tissue
samples were ﬁxed in 4% paraformaldehyde for 30 min at 48C.
After three washes with phosphate buffered saline (PBS) pH 7.4,
the sections were incubated overnight with X-gal staining solution
at 378C. Then, the sections were washed twice in PBS, counter-
stained with haematoxylin, dehydrated with ethanol and xylene
and coverslipped with entalan.
Endothelial immunohistochemistry
In order to investigate transfected cells in relationship to the
tumour vasculature cryosections were ﬁrst stained by the X-gal
method (see above) and secondly counter stained using a mouse-
anti-rat antibody against rat endothelial cell antigen (RECA-1,
Instruchemie, Hilversum, The Netherlands). After overnight X-gal
staining sections were thoroughly rinsed with PBS. RECA-1 was
diluted 1:10 in PBS and cryosections were incubated for 1 h.
Thereafter sections were rinsed with PBS and incubated for 1 h
with 1:100 diluted, in 5% normal rat serum in PBS, goat-anti-
mouse peroxidase labelled antibody (DAKO, Carpenteria, CA,
USA). After rinsing with PBS, positive cells were revealed by
immunoperoxidase reaction with DAB-solution (DAB-kit, DAKO)
and counter stained with haematoxylin.
In vivo anti-tumour efﬁcacy study
The various treatment modalities were started at a tumour size of
5–6 mm in diameter about 14 days after implantation of the
tumour. After start of treatment tumour size was measured via a
small midline laparotomy every fourth day. Tumour volume was
calculated by using the following formula: tumour volu-
me=A
26B60.4. In which B is the largest diameter and A the
diameter perpendicular to B, measured with a standardized calliper.
In every treatment group, control rats were included. The
AV1.0CMV construct was used as negative control in the efﬁcacy
study. In each treatment group, except for the 56HAI treated rats,
two animals were sacriﬁced 24 h after start of treatment in order to
collect tumour and liver tissue. Tissues were snap frozen in liquid
nitrogen and stored at 7808C until usage for immunohistochem-
istry.
Y28 immunohistochemistry
Cryosections of snap frozen tissue samples were ﬁxed in acetone
for a few seconds. After three washes with PBS/Tween for
15 min the sections were incubated for 60 min with the 1:2000
diluted polyclonal rabbit anti-Y28 antibody (kindly provided by
M Janicot, Institute Curie, Paris, France) at room temperature.
After incubation the sections were washed twice in PBS/0.5%
BSA, and incubated for 60 min with 1:20 diluted FITC-conjugated
F(ab')2 fragment of swine anti-rabbit immunoglobuline (Dako,
Glostrup, Denmark). The sections were again washed with PBS/
0.5% BSA. Afterwards slides were coverslipped with 90% PBS/
glycerol and immediately analyzed and photographed with a Leica
DM-RXA ﬂuorescence microscope equipped with a Sony DXC950
digital camera.
Toxicity study
In order to determine possible toxicity of the virus, rats were
weighed every 4 days after start of treatment. Four days after treat-
ment blood samples were taken via the tail vein. Serum was
collected after centrifugation (14000 r.p.m.) and stored at
7808C until further analysis. Liver functions (alkaline phospha-
tase, alaline aminotransferase, aspartate aminotransferase, total
bilirubin and g-glutamyl transpeptidase) and renal functions (crea-
tinin and urea) were measured by spectophotometric analysis
(ELAN-analyzer; Eppendorf-Merck, Hamburg, Germany). Throm-
bocyte, leukocyte, and erythrocyte numerations were also
determined in these samples (Sysmex; Kyoto, Japan).
Statistical analysis
In vitro and in vivo results were evaluated for statistical signiﬁcance
with the Kruskal–Wallis and Mann–Whitney U-tests with SPSS8.0
for Windows 98. A signiﬁcance level of P50.05 was used.
RESULTS
In vitro transfection efﬁcacy and cytotoxicity study
Cells were incubated with different concentrations of the
AV.1.0CMV.LacZ construct. After X-gal staining the percentage
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Table 1 Responses of CC531 tumours in vivo on day 20 after start of
treatment with AV1.0.CMV.Y28 (Y28) or AV1.0CMV (empty)
Treatment
Responses
a
model
b Rats (n)P DS DP RC RR R
c (%)
IT Y28 4 4 – – – 0
IT empty 4 4 – – – 0
IHP Y28 4 4 – – – 0
IHP empty 4 4 – – – 0
16HAI Y28 4 4 – – – 0
16HAI empty 4 4 – – – 0
56HAI Y28 8 4 – 1 3 50
56HAI empty 4 4 – – – 0
IV Y28 4 4 – – – 0
IV empty 4 4 – – – 0
aResponses were scored by measurement of tumour size as described in Materials
and Methods; PD: progressive disease growth=425%, SD: stable disease=growth
525% increase or 525% decrease of tumour size, PR: partial response=450%
growth reduction, CR: complete response=disappearance of all detectable disease.
bIT=intratumoural injection, IHP=isolated hepatic perfusion, 16HAI=single time
hepatic artery infusion, 56HAI=ﬁve times repeated hepatic artery infusion,
IV=intravenous injection;
cRR=response rate: percentage of rats with PR and CR.
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Figure 2 Growth of CC531 colon carcinoma cells in vitro after exposure
to increasing concentrations of AV.1.0CMV.Y28 (Y28) or AV1.0CMV
(empty). Five independent assays were performed in duplicate for each
point on the line. Mean values (+s.e.m.) are shown.
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scopy. The concentration of virus required to achieve a 50%
transfection rate was determined as TD 50 (Transfection Dose).
Our estimated TD 50 in this experiment was determined at a
MOI of 10000. The maximum percentage of transfected cells was
64% at a MOI of 20000. Above this concentration incubation of
CC531 cells with LacZ virus resulted in cell death.
Inhibition of proliferation of CC531 cells was observed with
both constructs at a MOI higher than 2000. However, the Y28
construct showed a much stronger inhibition (Figure 2). The
MOI resulting in 50% growth inhibition (ID 50) was 15000 for
the Y28 construct and 89000 for the empty construct. Therefore
next to a direct cytotoxic effect of the adenovirus, an additive inhi-
bitory effect of Y28 on CC531 cells in vitro was demonstrated.
In vivo transduction efﬁcacy study
X-gal staining of cryosections and the Y28 immunohistochemistry
studies revealed a needle track transfection pattern of tumour cells
after intratumoural injection, with an estimated percentage of posi-
tive cells 5% (Figure 3A). After IHP scattered foci of positive
tumour cells per frozen section could be observed, 2–3% positive
cells (Figure 3B). Almost no transfected tumour cells could be
detected after single time intravenous or repeated (ﬁve times)
intravenous or a single time hepatic artery infusion. After repeated
HAI (56HAI) however clear foci of transfection of tumour vascu-
lature and peri-tumour vasculature transfection were observed,
estimated 2–3% positive cells (Figures 3C and 4). Surprisingly,
low transfection levels (+1%) were observed in liver tissue in all
groups.
In vivo anti-tumour efﬁcacy study
In correspondence with the ﬁndings of the transduction efﬁcacy
study, intratumoural injection, intravenous injection, single time
hepatic artery infusion and isolated hepatic perfusion with the
Y28 construct did not result in any tumour response. All of
the treated rats demonstrated progressive disease (Table 1). Only
the tumours injected IT with Y28 showed a slight, inhibition
growth rate compared to empty construct. Strikingly, ﬁve times
repeated hepatic artery infusion showed a complete response in
three out of eight rats, a partial response in one rat and a
growth inhibition in the other four tumours, resulting in an
overall response rate of 50% (P50.02 on day 12 and P50.05
on day 16, compared to controls). All rats treated by 56HAI
with the empty construct demonstrated progressive disease
(Figure 5). As a consequence of these results we performed ﬁve
times repeated intravenous administration Y28 as an additive
control group. This repeated treatment resulted in progressive
disease in all animals (Table 1).
Toxicity study
No severe hepatic, renal or hematological toxicity could be detected
in any group after treatment with the Y28 or the empty construct.
Sera from rats treated by repeated hepatic artery infusion were
collected at day 8 after start of treatment. Levels of toxicity para-
meters measured in sera varied in a range of + and – 25% of
the control values. The only abnormality observed was a doubling
of g-glutamyl transpeptidase (gGT) levels, which was detected in all
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Figure 3 (A,B,C) Y28 ﬂuorescence immunohistochemistry on cryosections of tumours collected 24 h after treatment in vivo with AV.1.0CMV.Y28 (Y28).
(A) Tumour after IT, transfection around the needle track. (B) Foci of Y28 expression in tumour after IHP. (C) Expression in tumour after HAI. Original
magniﬁcation: A, B and C:1 6 6, insert 406. No staining was found in case of treatment with AV1.0CMV.
Figure 4 Two examples of X-gal stained and RECA stained cryosections
of tumours of different animals after HAI treatment with AV.1.0CMV.LacZ.
Tumour vessel (brown) and perivascular orientation of transfected cells
(blue) are clearly visible. Original magniﬁcation: 406. No staining was
found in case of treatment with AV1.0CMV.
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administration. Most changes in toxicity parameters seemed to
be due to the surgical procedure or the viral constructs rather than
the encoded gene. Haematological parameters showed a normal
leukocyte count after IHP with Y28, but in all other groups there
was a rise in leukocytes. The course of animal weights showed a
decrease of 5%, except for IHP and 56HAI treated rats, in which
a transient weight loss of at maximum 10% was observed.
DISCUSSION
For successful cancer gene therapy, tumour targeting is essential.
This can be achieved by adjusting the vector, but also by adjusting
vector delivery (Huard et al, 1995). In the present study, the aim
was to target a poor vascularized colorectal tumour located in liver
tissue and to study anti-tumour efﬁcacy by targeting p21-ras. Deliv-
ery via intratumoural injection is an established method to achieve
transfection but its clinical applicability is limited. We consider a
transvascular approach a prerequisite for testing the real therapeutic
window of gene therapy. IHP and HAI are transvascular administra-
tion modalities, which give rise to high local concentrations of the
drug throughout the liver. de Wilt et al (2001) successfully
performed isolated limb perfusion in sarcoma-bearing rats for the
transfer of the IL-3b-gene. The IL-3b cytokine was excreted upon
transfection of the cells and thereby induced a major bystander
effect in this tumour model, which resulted in excellent tumour
responses. The BN-175 tumour used in the IL-3b study is a high
grade, rapidly growing tumour with an extensive vascularization.
These characteristics offer superior possibilities for transfection. Fast
growing tumours are more susceptible for genes driven by a CMV
promoter (Ghazal et al, 1987). In contrast to the BN-175 tumour,
CC531 tumours have a slow growth rate and are poorly vascular-
ized. Apart from that, the immunologic activity of the liver, in
comparison with a limb, is enormous.
In vitro transfection studies demonstrated that transfection of
CC531 cells is possible. In a pilot study we investigated other cell
lines as well and the transfection efﬁcacy was equal compared to
the colon carcinoma cell line used in this study. The in vitro cyto-
toxicity assay of AV.1.0CMV.Y28 construct showed effective
tumour growth inhibition and cytotoxicity on CC531 cells. The
TD 50 in the transfection efﬁcacy study is about equal to the ID
50 of AV.1.0CMV.Y28 in the cytotoxicity assay. This strongly
suggests that transfection of the ras mutated CC531 cells with
Y28 anti-ras antibody results in proliferation inhibition. Next to
this we performed in vitro bioassays on human umbilical vein
derived endothelial cells (HUVECs) which do not harbour a ras
mutation. On HUVECs AV.1.0CMV.Y28 hardly results in growth
inhibition compared with the CC531 cell line (data not shown).
In vivo IT injection shows signiﬁcant transfection of tumour
cells on X-gal stained cryosections and immunohistochemistry.
Strikingly, a single administration of AV.1.0CMV.Y28 intra-
tumourally did not result in a signiﬁcant tumour response. This
can be explained by the fact that IT injection results in transfec-
tion around the needle track only. A trans-endothelial route
causes a more homogeneous distribution of transfection of the
tumour. We have reported this previously in the rat sarcoma
model particularly at the viable rim of the tumour (de Roos
et al, 2000).
Bilbao et al (2000) found that a blood–tumour barrier in hepa-
to-cellular carcinoma in rats limits the gene transfer in tumours
greater than 5 mm in diameter. Moreover, they also concluded that
tumours between 2 and 5 mm could only be transfected by hepatic
artery infusion. As already mentioned we started treatment at a
tumour diameter of about 5 mm, so a blood–tumour barrier
may well play a role in the limited transvascular transfection we
observed. After multiple HAI, the transfection rate of tumour tissue
still remains low, however in the AV1.0CMV.LacZ and Y28
immunohistochemistry experiments transfection could be demon-
strated around tumour vessels.
It is known that down regulation of p21-ras causes a
decrease of vascular endothelial growth factor (VEGF) produc-
tion (Arbiser et al, 1997; Okada et al, 1998; Zhang et al,
2001). A bystander effect caused by down regulation of VEGF
after p53-gene therapy in vivo has already been described
(Bouvet et al, 1998). Expression of the Y28 construct may cause
an anti-angiogenic effect by this ras-VEGF-pathway. A higher
transfection of perivascular tumour cells and, as a consequence
of this, a reduction of VEGF levels around tumour vessels upon
56HAI could play a role in the anti tumour effect we
observed.
Our experiments indicate that indirect immunological anti-
tumour effect by repeated adenovirus administration can be
ruled out, because not only ﬁve times repeated HAI with
the empty control vector, but also ﬁve times repeated intra-
venous administration with AV1.0.CMV.Y28 did not result
in any anti-tumour efﬁcacy. We conclude that it is a
prerequisite to deliver this vector loco-regionally and in a
repetitive way.
Targeted gene therapy is a major issue in the development of
gene therapy towards clinical trials. Furthermore, gene therapy
has to be safe. In this study we report on a successful repeated
administration of adenoviral vectors without signiﬁcant toxicity.
We demonstrated that loco-regional gene therapy of slowly
progressing, poorly vascularized colon carcinoma liver metastases
is feasible and that repeated treatment might offer possibilities
for future gene therapy trials.
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